Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.73 |
| ▸ | HTR2A | P28223 | 2/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | SCN1A | P35498 | 1/20 | 0.73 |
| ▸ | HTR2B | P41595 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.73 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.73 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.73 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.69 |
| ▸ | DRD2 | P14416 | 1/20 | 0.69 |
| ▸ | HRH1 | P35367 | 1/20 | 0.69 |
| ▸ | DRD3 | P35462 | 1/20 | 0.69 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12128299 | 0.93 | ALDH1A1 (0.70) | ALDH1A1HTTTSHRKDM4E | |
| SCHEMBL6452945 | 0.91 | NPC1 (0.79) | MAPK1HTR2ASIGMAR1ALDH1A1CYP1A2 | |
| SCHEMBL27544865 | 0.91 | HRH3 (0.65) | MAPK1HTR2ASIGMAR1ALDH1A1CYP1A2 | |
| SCHEMBL11899308 | 0.91 | RAB9A (0.83) | MAPK1HTR2ASIGMAR1ALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7013705 | 0.90 | NPC1 (0.82) | MAPK1USP2LMNANPC1RAB9A | |
| SCHEMBL14204567 | 0.90 | NPC1 (0.77) | ALDH1A1NPC1RAB9ALTA4HTSHR | |
| SCHEMBL7008655 | 0.89 | TSHR (0.76) | MAPK1HTR2ASIGMAR1ALDH1A1CYP1A2 | |
| SCHEMBL7033807 | 0.87 | HTR1A (0.80) | HTR2ASIGMAR1ALDH1A1HRH3HTR1A | |
| Pramoxine SCHEMBL26020 | 0.85 | ALDH1A1 (1.00) | MAPK1HTR2ASIGMAR1ALDH1A1CYP1A2 | |
| SCHEMBL13891668 | 0.84 | PSMB1 (0.63) | MAPK1HTR2ASIGMAR1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2026-03-24 | — | — | US | disclosed |
| EP-4065553-B1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | DAEGU GYEONGBUK MEDICAL INNOVATION FOUND (KR) | 2025-01-29 | — | — | EP | disclosed |
| CN-114981241-B | Novel compounds, process for their preparation and their use | 大邱庆北尖端医疗产业振兴财团 | 2024-11-19 | — | — | CN | disclosed |
| CN-112424194-B | Immunomodulator, composition and preparation method thereof | 贝达药业股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-4065553-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2022-10-05 | — | — | EP | disclosed |
| CN-114981241-A | Novel compound, preparation method and application thereof | 大邱庆北尖端医疗产业振兴财团 | 2022-08-30 | — | — | CN | disclosed |
| CN-112424194-A | Immunomodulator, composition and preparation method thereof | 贝达药业股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| CN-100396675-C | Prodrugs of proton pump inhibitors | PARTNERSHIP OF MICHAEL E GAST (US) | 2008-06-25 | — | — | CN | disclosed |
| WO-2007018941-A2 | PYRIMIDYL-THIOPHENE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| US-6559167-B1 | Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-05-06 | — | — | US | disclosed |
| EP-1105387-B1 | PRODRUGS OF PROTON PUMP INHIBITORS | WINSTON PHARMATEUTICALS LLC (US) | 2003-01-29 | — | — | EP | disclosed |
| CN-1312806-A | Prodrugs of proton pump inhibitors | PARTNERSHIP OF MICHAEL E GAST (US) | 2001-09-12 | — | — | CN | disclosed |
| EP-1105387-A1 | PRODRUGS OF PROTON PUMP INHIBITORS | Partnership of Michael E. Garst, George Sachs and Jai Moo Shin (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000009498-A1 | PRODRUGS OF PROTON PUMP INHIBITORS | PARTNERSHIP OF MICHAEL E. GARST, GEORGE SACHS AND JAI MOO SHIN (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | TYRO3, TH, SRMS | MAPK1 828/4885HTR2A 532/4885SIGMAR1 234/4885 |
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | AURKA, AURKC, AURKB | MAPK1 3452/4885HTR2A 3737/4885SIGMAR1 3032/4885 |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | TYR, TYRO3, TH | MAPK1 727/4885HTR2A 1526/4885SIGMAR1 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.